Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy.

MRD作为抗白血药物疗效标志,被评估患者,某些例中调整治疗强度。

Leukemic cells from patients with acute leukemia were treated with different antileukemic agents in microwell liquid culture,then the cytotoxicity was measured with MTT assay.

将白血细胞与化疗药物微孔液体培养，MTT法检测细胞毒性。